ORTHOPEDIATRICS CORP (KIDS) earnings date
Mar 2, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 14 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Tue, Oct 27, 2026 | after close | 27 | 8-K |
| Q2 FY2026 | Tue, Aug 4, 2026 | after close | 35 | 8-K |
| Q1 FY2026 | Thu, Apr 30, 2026 | after close | 30 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | after close | 57 | 8-K |
| Q3 FY2025 | Tue, Oct 28, 2025 | after close | 28 | 8-K |
| Q2 FY2025 | Tue, Aug 5, 2025 | after close | 36 | 8-K |
| Q1 FY2025 | Wed, May 7, 2025 | after close | 37 | 8-K |
| Q4 FY2024 | Tue, Mar 4, 2025 | after close | 63 | 8-K |
What they guided beta
| Q3 FY2026 | "Document OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance Record Third Quarter 2026 Revenue of $72.7 Million, Up 19% Year-over-Year WARSAW, Ind., October 27, 2026 -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2026." exhibit |
| Q3 FY2026 | "Increased full year 2026 revenue guidance to $270.0 million to $273.0 million from its prior range of $265.0 million to $269.0 million, representing growth of 14% to 16% compared to prior year “In the third quarter, we continued to build on the momentum in our business, gaining share in Trauma and Deformity and Scoliosis globally, and continued substantial progress with our OPSB strategy." exhibit |
| Q3 FY2026 | "Full Year 2026 Financial Guidance For the full year of 2026, the Company is increasing its revenue guidance to $270.0 million to $273.0 million from its prior range of $265.0 million to $269.0 million, representing growth of 14% to 16% over 2025 revenue." exhibit |
| Q3 FY2026 | "The Company reiterated it expects annual set deployment to be approximately $10.0 million, expects adjusted EBITDA of approximately $25.0 million, and expects to achieve breakeven free cash flow in 2026." exhibit |
| Q2 FY2026 | "Document OrthoPediatrics Corp. Reports Second Quarter 2026 Financial Results and Increases 2026 Financial Guidance Second Quarter 2026 Revenue Surpasses $70 million for the First Time in Company History, and Increased 15% Year-over-Year WARSAW, Ind., August 4, 2026 -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the second quarter ended June 30, 2026." exhibit |
| Q2 FY2026 | "Increased full year 2026 revenue guidance to $265.0 million to $269.0 million from its prior range of $263.0 million to $267.0 million, representing growth of 12% to 14% compared to prior year David Bailey, President & CEO of OrthoPediatrics, commented, “We have reached the beginning of an inflection point in our business as our second quarter results demonstrate our ability to simultaneously drive stronger revenue growth, increase profitability, and improve free cash flow." exhibit |
| Q2 FY2026 | "Full Year 2026 Financial Guidance For the full year of 2026, the Company is increasing its revenue guidance to $265.0 million to $269.0 million from its prior range of $263.0 million to $267.0 million, representing growth of 12% to 14% over 2025 revenue." exhibit |
| Q2 FY2026 | "The Company reiterated it expects annual set deployment to be approximately $10.0 million, expects adjusted EBITDA of approximately $25.0 million, and expects to achieve breakeven free cash flow in 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/KIDS
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/KIDS
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/KIDS/"><img src="https://veritasdata.dev/embed/KIDS.svg" alt="KIDS earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/KIDS/)
Script
<script async src="https://veritasdata.dev/embed/KIDS.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/KIDS"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.